Compare DexCom, Inc. (DXCM) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs The Coca-Cola Co K — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while The Coca-Cola Co K trades at $87.35 (market cap $369.24B). The key difference: The Coca-Cola Co K is far larger — about 11.6× DexCom, Inc.'s market cap, and The Coca-Cola Co K pays a 2.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and The Coca-Cola Co K for 154 Days on average.
| DXCM | KO | |
|---|---|---|
Market Cap | $31.81B | $369.24B |
Volume | 2,861,821 | 12,951,290 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $91.99 |
52-Week Low | $54.84 | $66.37 |
Typical Hold Time | 62 Days | 154 Days |
Enterprise Value | $31.26B | $396.42B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Coca-Cola (KO) trades at $87.77, up 1.86% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 28.56% net income margin and 44.23% ROE, supported by consistent revenue growth. Analyst consensus is bullish with a $95.75 price target, though technical indicators highlight near-term resistance at $86-$87. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive given KO's dividend track record and earnings momentum, but risks include regional demand volatility and high debt levels. Upside is supported by analyst targets, while technical weakness near key resistance may limit short-term gains. The stock offers value for income-focused investors despite macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
